Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 1;32(3):294-300.
doi: 10.1097/ICU.0000000000000746.

Emerging treatments for geographic atrophy in age-related macular degeneration

Raziyeh Mahmoudzadeh  1 , John W Hinkle, Jason Hsu, Sunir J Garg
Affiliations
Review

Emerging treatments for geographic atrophy in age-related macular degeneration

Raziyeh Mahmoudzadeh et al. Curr Opin Ophthalmol. .

Abstract

Purpose of review: This review describes therapeutic research programs for geographic atrophy (GA) due to age-related macular degeneration (AMD). We highlight clinical trial data from phase I, II, and III studies.

Recent findings: There are currently no treatments for GA, a form of advanced AMD that causes significant visual morbidity. Currently, therapeutic candidates are being developed to delay further progression of GA or even attempt to reverse some of the damage. The approaches to therapy range from molecular targets to cell transplantation. Studies of these novel treatment approaches have demonstrated varying degrees of success. The progress in understanding the disease pathophysiology as well as clinical trial data is reviewed.

Summary: There are promising new treatments to prevent GA progression as well as some that may reverse the disease course.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vitale S, Agrón E, Clemons TE, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS Report 41. JAMA Ophthalmol 2020; 138:610–617.
    1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014; 2:e106–e116.
    1. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet 2018; 392:1147–1159.
    1. Sivaprasad S, Tschosik EA, Guymer RH, et al. Living with geographic atrophy: an ethnographic study. Ophthalmol Ther 2019; 8:115–124.
    1. Rudnicka AR, Kapetanakis VV, Jarrar Z, et al. Incidence of late-stage age-related macular degeneration in american whites: systematic review and meta-analysis. Am J Ophthalmol 2015; 160:85–93. e3.

MeSH terms

LinkOut - more resources